GlycoMimetics (NASDAQ:GLYC) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of GlycoMimetics (NASDAQ:GLYC) in a report issued on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.

A number of other equities analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a neutral rating on shares of GlycoMimetics in a research note on Monday, May 6th. Capital One Financial cut shares of GlycoMimetics from an overweight rating to an equal weight rating in a report on Monday, May 6th.

GlycoMimetics Price Performance

Shares of NASDAQ:GLYC opened at $0.27 on Wednesday. GlycoMimetics has a 52 week low of $0.26 and a 52 week high of $3.53. The company has a 50-day moving average price of $1.82 and a 200 day moving average price of $2.24. The company has a market cap of $17.40 million, a P/E ratio of -0.47 and a beta of 2.30.

GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings results on Wednesday, March 27th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. The business had revenue of $0.01 million during the quarter. Analysts expect that GlycoMimetics will post -0.63 EPS for the current year.

Institutional Investors Weigh In On GlycoMimetics

Several institutional investors and hedge funds have recently made changes to their positions in GLYC. Acuta Capital Partners LLC acquired a new position in GlycoMimetics during the third quarter worth about $41,000. MJP Associates Inc. ADV acquired a new position in shares of GlycoMimetics during the 4th quarter worth approximately $238,000. Advisor OS LLC purchased a new stake in GlycoMimetics in the 4th quarter valued at approximately $238,000. Finally, Vanguard Group Inc. grew its holdings in GlycoMimetics by 14.0% during the 1st quarter. Vanguard Group Inc. now owns 2,761,981 shares of the biotechnology company’s stock valued at $8,286,000 after buying an additional 340,112 shares during the last quarter. 75.19% of the stock is currently owned by hedge funds and other institutional investors.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.